The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT)

Clinical and Experimental Allergy

Volumn 29, Issue 7, 1999, Pages 896-904

  Valenta, R ^a   Lidholm, J ^b   Niederberger, V ^a   Hayek, B ^a   Kraft, D ^a   Gronlund H ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; POLLEN ANTIGEN;

ALLERGY; ATOPY; CROSS REACTION; DNA RECOMBINATION; GRASS POLLEN; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0005629635     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1999.00653.x     Document Type: Review

References (68)

1. Kay AB. Allergy and Allergic Diseases. Oxford: Blackwell Science 1997.
2. Casolaro S, Georas SN, Song Z, Ono SJ. Biology and genetics of atopic disease. Curr Opin Immunol 1996; 8:796-803.
3. Ishizaka K, Ishizaka T, Hornbrook MM. Physicochemical properties of human reaginic antibody. J Immunol 1966; 97:840-5.
4. Johannson SGO, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967; 13:381-94.
5. Segal DM, Taurog JD, Metzger H. Dimeric immunoglobulin E serves as a unit signal for mast cell degranulation. Proc Natl Acad Sci USA 1977; 41:457-67.
6. Kay AB, Barata L, Meng Q, Durham SR, Ying S. Eosinophils and eosinophil-associated cytokines in allergic inflammation. Int Arch Allergy Immunol 1997; 113:196-9.
7. Stingl G, Maurer D. IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Int Arch Allergy Immunol 1997; 113:24-9.
8. Bousquet J, Lockey R, Mailing HJ and the WHO panel members. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-62.
9. Durham SR, Till SJ. Immunological changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102:157-64.
10. Valenta R, Kraft D. Recombinant allergens for diagnosis and therapy of allergic diseases. Curr Opin Immunol 1995; 7:751-6.
11. Valenta R, Vrtala S, Laffer S, Spitzauer S, Kraft D. Recombinant allergens. Allergy 1998; 53:552-61.
12. Lockey RF, Bukantz SC, eds, Allergen immunotherapy, 2nd edn. New York, NY: Marcel Dekker, 1998.
13. Freidhoff LR, Ehrlich-Kautzky E, Grant JH, Meyers DA, Marsh DG. A study of the human immune response to Lolium perenne (rye) pollen and its components, Lol p 1 and Lol p 2 (rye 1 and rye 2). J Allergy Clin Immunol 1986; 78:1190-201.
14. Studier FW, Rosenberg AH, Dunn JJ, Dubendorff JW. Use of T7 RNA polymerase to direct expression of cloned genes. Meth Enzymol 1990; 185:60-89.
15. Van Dyke MW, Sirito M, Sawadogo M. Single-step purification of bacterially expressed polypeptides containing an oligohistidine domain. Gene 1992; 111:99-104.
16. van der Veen Mj, Mulder M, Witteman AM et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens. J Allergy Clin Immunol 1996; 98:1028-34.
17. Mittermann I, Swoboda I, Pierson E et al. Molecular cloning and characterization of profilin from tobacco (Nicotiana tabacum): Increased profilin expression during pollen maturation. Plant Mol Biol 1995; 27:137-46.
18. Crameri R. Recombinant Aspergillus fumigatus allergens: from the nucleotide sequences to clinical applications. Int Arch Allergy Immunol 1998; 115:99-114.
19. Bousquet J, Valenta R. In vivo and in vitro use of recombinant allergens. ACI Intern 1994; 6:54-9.
20. Ebner C, Hirschwehr R, Bauer L et al. Identification of allergens in fruits and vegetables. IgE-crossreactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). J Allergy Clin Immunol 1995; 95:962-9.
21. Valenta R, Kraft D. Type I allergic reaclions to plant-derived food: a consequence of primary sensitization to pollen allergens. J Allergy Clin Immunol 1996; 97:893-5.
22. Valenta R, Steinberger P, Duchêne M, Kraft D. Irnmunological and structural similarities among allergens: Prerequisite for a specific and component-based therapy of allergy. Immunol Cell Biol 1996; 74:187-94.
23. Valenta R, Duchêne M, Vrtala S et al. Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J Allergy Clin Immunol 1991; 88:889-94.
24. Valenta R, Vrtala S, Ebner C, Kraft D, Scheiner O. Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens. Int Arch Allergy Immunol 1992; 97:287-94.
25. Laffer S, Spitzauer S, Susani M et al. Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. J Allergy Clin Immunol 1996; 98:625-58.
26. Laffer S, Vrtala S, Duchêne M et al. IgE binding capacity of recombinant timothy grass (Phleum pratense) pollen allergens. J Allergy Clin Immunol 1994; 94:88-94.
27. Ball T, Sperr WR, Valent P et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999, in press.
28. Twardosz A, Hayek B, Seiberler S et al. Molecular characterization, expression in Escherichia coli, and epitope analysis of a two EF-hand calcium-binding birch pollen allergen, Bet v 4. Biochem Biophys Res Comm 1997; 239:197-204.
29. Engel E, Richter K, Obermeyer G et al. Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains. J Biol Chem 1997; 272:28630-7.
30. Hayek B, Vangelista L, Pastore A et al. Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: Structural basis for calcium-modulated IgE recognition. J Immunol 1998; 161:7031-9.
31. Batanero E, Villalba M, Ledesma A, Puente XS, Rodriguez R. Ole e 3, an olive-tree allergen, belongs to a widespread family of pollen proteins. Eur J Biochem 1996; 241:772-8.
32. +-binding proteins (polcalcins) involved in allergy. Eur J Biochem 1998; 258:454-9.
33. Suphioglu C, Ferreira F, Knox RB. Molecular cloning and immunological characterization of Cyn d 7, a novel calcium-binding allergen from Bermuda grass pollen. FEBS Lett 1997; 402:167-72.
34. + binding protein as a new Bermuda grass pollen allergen Cyn d 7: IgE cross-reactivity with oilseed rape pollen allergen Bra r 1. Int Arch Allergy Immunol 1997; 114:265-71.
35. Niederberger V, Hayek B, Vrtala S et al. Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a crossreactive two EF-hand timothy grass pollen allergen, Ph1 p 7. FASEB J 1999; 13:843-56.
36. +-binding proteins. Plant Mol Biol 1995; 29:1157-65.
37. Valenta R, Duchene M, Pettenburger K et al. Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 1991; 253:557-60.
38. Valenta R, Duchêne M, Ebner C et al. Profilins constitute a novel family of functional plant pan-allergens. J Exp Med 1992; 175:377-85.
39. Vallier P, Dechamp C, Valenta R, Vial O, Deviller P. Purification and characterization of an allergen from celery immunochemically related to an allergen present in several other plant species. Identification as a profilin. Clin Exp Allergy 1992; 22:774-82.
40. vanRee R, Voitenlo V, van Leeuwen WA, Aalberse RC. Profilin is a cross-reactive allergen in pollen and vegetable food. Int Arch Allergy Immunol 1992; 98:97-104.
41. Vallier P, Balland S, Harf R, Valenta R, Deviller P. Identification of profilin as an IgE-binding component in latex from Hevea brasiliensis: clinical implications. Clin Exp Allergy 1994; 25:332-9.
42. Spitzauer S, Schweiger C, Sperr WR et al. Molecular characterization of dog albumin as a crossreactive allergen. J Allergy Clin Immunol 1994; 93:614-27.
43. Breiteneder H, Pettenburger K, Bito A et al. The gene coding for the major birch pollen allergen, Bet v 1, is highly homologous to a pea disease resistance response gene. EMBO J 1989; 8:1935-8.
44. Jensen-Jarolim E, Leitner A, Hirschwehr R et al. Characterization of allergens in Apicaceae species: anise, fennel, coriander and cumin. Clin Exp Allergy 1997; 27:1299-306.
45. Swoboda I, Jilek A, Ferreira F et al. Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning. J Biol Chem 1995; 270:2607-13.
46. Chua KY, Kehal PK, Thomas WR, Vaughan PR, Macreadie IG. High-frequency binding of IgE to the Der p allergen expressed in yeast. J Allergy Clin Immunol 1992; 89:95-102.
47. Niederberger V, Pauli G, Grönland H et al. Recombinant birch pollen allergens (rBet v 1, rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen. A quantitative IgE inhibition study using sera from different populations. J Allergy Clin Immunol 1998; 102:579-91.
48. Niederberger V, Laffer S, Fröschl R et al. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol 1998; 101:258-64.
49. Noon L. Prophylactic inoculation against hayfever. Lancet 1911; 1:1572-3.
50. Norman PS, Lichtenstein LM, Kagey-Sobotka A, Marsh DG. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol 1982; 70:248-60.
51. Van Ree R, van Leeuwen WA, Dieges PH et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin Exp Allergy 1997; 27:68-74.
52. Vrtala S, Ball T, Spitzauer S et al. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J Immunol 1998; 160:6137-44.
53. Ball T, Vrtala S, Sperr WR et al. Isolation of an immunodominant IgE-hapten from an epitope expression cDNA library; dissection of the allergic effector reaction. J Biol Chem 1994; 269:28323-8.
54. Vrtala S, Hirtenlehner K, Vangelista L et al. Conversion of the major birch pollen allergen, Bet v 1, into two non-anaphylactic T cell epitope-containing fragments. Candidates for a novel form of specific immunotherapy. J Clin Invest 1997; 99:1673-81.
55. Zeiler T, Taivainen A, Rytkonen M et al. Recombinant allergen fragments as candidate preparations for allergen immunotherapy. J Allergy Clin Immunol 1997; 100:721-7.
56. Ferreira F, Hirtenlehner K, Jilek A et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996; 183:599-609.
57. Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996; 33:399-405.
58. Takai T, Yokota T, Yasue M et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy, Nat Biotechnol 1997; 15:754-8.
59. Ferreira F, Ebner C, Kramer B et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J 1998; 12:231-42.
60. Okada T, Swoboda I, Bhalla PL, Toriyama K, Singh MB. Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy. FEBS Lett 1998; 434:255-60.
61. Valenta R, Almo S, Ball T et al. The immunoglobulin E-allergen interaction: a target for therapy of type I allergic diseases. Int Arch Allergy Immunol 1998; 116:167-76.
62. Schramm G, Kahlert H, Suck R et al. Allergen engineering: Variants of timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J Immunol 1999; 162:2406-14.
63. Vrtala S, Hirtenlehner K, Susani M et al. Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: Candidates for specific immunotherapy. Int Arch Allergy Immunol 1999; 118:218-9.
64. van Hage-Hamsten M, Kronqvist M, Zetterström O et al. Skin lest evaluation of genetically engineered hypoallergenic derivates of the major birch pollen allergen, Bet v 1. Results obtained with a mix of two recombinant Bet v 1 fragments and rBet v 1 trimer in a Swedish population before the birch pollen season. Submitted.
65. Pauli G, Purohit A, Oster JP et al. Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivates by skin prick and intradermal testing: results obtained in a French population. Submitted.
66. Kolbe L, Hausser C, Kolsch E. Antigen dose dependent regulation of B epsilon-memory cell expression. Int Arch Allergy Immunol 1991; 95:202-6.
67. + T cells from allergic individuals is modulated by antigen concentration and antigen-presenting. J Exp Med 1995; 181:1081-9.
68. Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998; 28:914-25.